Ann Surg Oncol September 2024 PMID 38879670

Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.

Phoebe N Miller, Fernanda Romero-Hernandez, Lucia Calthorpe, Jaeyun Jane Wang, Sunhee S Kim, Carlos U Corvera, Kenzo Hirose, Kimberly S Kirkwood, Ryutaro Hirose, Ajay V Maker, Adnan A Alseidi, Mohamed A Adam, Grace E Kim, Margaret A Tempero, Andrew H Ko

Mentions

4
Peak: 2 in Apr 2025
across 2 sources since Jun 2024

Extended reach

9,258
potential audience

Total likes

10

Video views

6,540

Mentions per month

Jun 2024 – Jun 2025

Where it's discussed

  • YouTube3 videos
  • X / Twitter1 posts

AI synopsis

What people are saying

The discussions highlight how many posters view the study as a promising advancement, with phrases like 'favorable outcomes' and 'potential game changer.' The tone indicates strong interest and a recognition of the study's possible impact on treatment protocols, with some posts exploring detailed aspects such as surgical success rates and survival benefits.

AgreementModerate agreement

Most discussions support the positive outcomes of long-duration FOLFIRINOX treatment, emphasizing its potential benefits for surgical results.

InterestHigh interest

Participants show high curiosity, often discussing the significance of this approach for pancreatic cancer management.

EngagementHigh engagement

Several posts delve into the methodology and implications, indicating active, in-depth engagement with the publication.

ImpactModerate impact

The discussions suggest the research could influence clinical strategies, though some recognize the need for further validation.

Abstract in brief

  • In 2023, over 64,000 patients are expected to be diagnosed with pancreatic ductal adenocarcinoma (PDAC), with more than 50,000 deaths projected, highlighting the critical need for effective treatment strategies.
  • Current guidelines suggest using neoadjuvant therapy, especially for patients with borderline resectable and locally advanced PDAC, as it may improve surgical outcomes by increasing R0 resection rates and helping identify unfavorable tumor biology.
  • This study indicates that long-duration neoadjuvant FOLFIRINOX therapy before surgical resection can lead to favorable survival outcomes and effective surgical results, regardless of the initial resectability status of the tumor.

Top posts

Most liked on X and Bluesky
STITCHES - the Best Papers in General Surgery
@stitchestoday · X

Long-Duration Neoadjuvant FOLFIRINOX Therapy for Pancreatic Cancer Surgery by Miller PN, Romero-Hernandez F (...) Nakakura EK et 13 al. in Ann Surg Oncol https://t.co/GoFUMSWSkO

Jun 25, 2024 · 2 likes · 2,719 followers View post →

All mentions

STITCHES - the Best Papers in General Surgery
@stitchestoday · X

Long-Duration Neoadjuvant FOLFIRINOX Therapy for Pancreatic Cancer Surgery by Miller PN, Romero-Hernandez F (...) Nakakura EK et 13 al. in Ann Surg Oncol https://t.co/GoFUMSWSkO

Jun 25, 2024 · 2 likes · 2,719 followers View post →